|
|
|
|
|
by WJW
1620 days ago
|
|
From the wikipedia page you linked: > Molnupiravir is indicated for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19.[1][5] So after the risk of creating mutations in the Covid virus has been assessed and weighed against the chances of patients just outright dying due to not having this medicine available, the board full of medical professionals trained in this matter voted 13 to 10 that they thought the risk was acceptable. |
|